Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus

Jorge L. Aguilar, Avanish K. Varshney, Ximo Pechuan, Kaushik Dutta, Joshua D. Nosanchuk, Bettina C. Fries

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Staphylococcus aureus is a leading infectious cause of life-threatening disease in humans, yet there is currently no vaccine to combat this bacterium. The pathogenesis of S. aureus is mediated by a diverse array of protein toxins including a large family of secreted pyrogenic superantigens. Neutralization of superantigens, including SEB and TSST-1, has proven to be protective in several animal models of toxic shock and sepsis. We demonstrate, for the first time, that a far more prevalent staphylococcal superantigen, SEK, can also induce lethal shock in mice. Additionally, we describe monoclonal antibodies (mAbs) that inhibit SEK-induced mitogenicity as well as protect against SEK-induced lethality, and enhance survival from S. aureus septicemia in murine models. MAb-4G3 (IgG2b), mAb-5G2 (IgG1), and mAb-9H2 (IgG1), all inhibit SEK-induced proliferation and cytokine production of human immune cells. We then demonstrate that passive immunization with a combination of mAb-4G3 and mAb-5G4, 2 mAbs that do not compete for epitope(s) on SEK, significantly enhance survival in a murine model of SEK-induced toxic shock (p = 0.006). In the setting of sepsis, passive immunization with this combination of mAbs also significantly enhances survival in mice after challenge with CA-MRSA strain USA300 (p = 0.03). Furthermore, septic mice that received mAb treatment in conjunction with vancomycin exhibit less morbidity than mice treated with vancomycin alone. Taken together, these findings suggest that the contribution of SEK to S. aureus pathogenesis may be greater than previously appreciated, and that adjunctive therapy with passive immunotherapy against SEs may be beneficial.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalVirulence
DOIs
StateAccepted/In press - Oct 26 2016

Fingerprint

Enterotoxins
Septic Shock
Staphylococcus aureus
Sepsis
Monoclonal Antibodies
Passive Immunization
Superantigens
Vancomycin
Survival
Immunoglobulin G
Protein Array Analysis
Methicillin-Resistant Staphylococcus aureus
Epitopes
Shock
Vaccines
Animal Models
Cytokines
Morbidity
Bacteria
Therapeutics

Keywords

  • Staphylococcal Enterotoxin B
  • Staphylococcal Enterotoxin K
  • toxic shock syndrome toxin 1

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. / Aguilar, Jorge L.; Varshney, Avanish K.; Pechuan, Ximo; Dutta, Kaushik; Nosanchuk, Joshua D.; Fries, Bettina C.

In: Virulence, 26.10.2016, p. 1-10.

Research output: Contribution to journalArticle

Aguilar, Jorge L. ; Varshney, Avanish K. ; Pechuan, Ximo ; Dutta, Kaushik ; Nosanchuk, Joshua D. ; Fries, Bettina C. / Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. In: Virulence. 2016 ; pp. 1-10.
@article{33521141b7bf4cc6b7afd43d9ecc728a,
title = "Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus",
abstract = "Staphylococcus aureus is a leading infectious cause of life-threatening disease in humans, yet there is currently no vaccine to combat this bacterium. The pathogenesis of S. aureus is mediated by a diverse array of protein toxins including a large family of secreted pyrogenic superantigens. Neutralization of superantigens, including SEB and TSST-1, has proven to be protective in several animal models of toxic shock and sepsis. We demonstrate, for the first time, that a far more prevalent staphylococcal superantigen, SEK, can also induce lethal shock in mice. Additionally, we describe monoclonal antibodies (mAbs) that inhibit SEK-induced mitogenicity as well as protect against SEK-induced lethality, and enhance survival from S. aureus septicemia in murine models. MAb-4G3 (IgG2b), mAb-5G2 (IgG1), and mAb-9H2 (IgG1), all inhibit SEK-induced proliferation and cytokine production of human immune cells. We then demonstrate that passive immunization with a combination of mAb-4G3 and mAb-5G4, 2 mAbs that do not compete for epitope(s) on SEK, significantly enhance survival in a murine model of SEK-induced toxic shock (p = 0.006). In the setting of sepsis, passive immunization with this combination of mAbs also significantly enhances survival in mice after challenge with CA-MRSA strain USA300 (p = 0.03). Furthermore, septic mice that received mAb treatment in conjunction with vancomycin exhibit less morbidity than mice treated with vancomycin alone. Taken together, these findings suggest that the contribution of SEK to S. aureus pathogenesis may be greater than previously appreciated, and that adjunctive therapy with passive immunotherapy against SEs may be beneficial.",
keywords = "Staphylococcal Enterotoxin B, Staphylococcal Enterotoxin K, toxic shock syndrome toxin 1",
author = "Aguilar, {Jorge L.} and Varshney, {Avanish K.} and Ximo Pechuan and Kaushik Dutta and Nosanchuk, {Joshua D.} and Fries, {Bettina C.}",
year = "2016",
month = "10",
day = "26",
doi = "10.1080/21505594.2016.1231295",
language = "English (US)",
pages = "1--10",
journal = "Virulence",
issn = "2150-5594",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus

AU - Aguilar, Jorge L.

AU - Varshney, Avanish K.

AU - Pechuan, Ximo

AU - Dutta, Kaushik

AU - Nosanchuk, Joshua D.

AU - Fries, Bettina C.

PY - 2016/10/26

Y1 - 2016/10/26

N2 - Staphylococcus aureus is a leading infectious cause of life-threatening disease in humans, yet there is currently no vaccine to combat this bacterium. The pathogenesis of S. aureus is mediated by a diverse array of protein toxins including a large family of secreted pyrogenic superantigens. Neutralization of superantigens, including SEB and TSST-1, has proven to be protective in several animal models of toxic shock and sepsis. We demonstrate, for the first time, that a far more prevalent staphylococcal superantigen, SEK, can also induce lethal shock in mice. Additionally, we describe monoclonal antibodies (mAbs) that inhibit SEK-induced mitogenicity as well as protect against SEK-induced lethality, and enhance survival from S. aureus septicemia in murine models. MAb-4G3 (IgG2b), mAb-5G2 (IgG1), and mAb-9H2 (IgG1), all inhibit SEK-induced proliferation and cytokine production of human immune cells. We then demonstrate that passive immunization with a combination of mAb-4G3 and mAb-5G4, 2 mAbs that do not compete for epitope(s) on SEK, significantly enhance survival in a murine model of SEK-induced toxic shock (p = 0.006). In the setting of sepsis, passive immunization with this combination of mAbs also significantly enhances survival in mice after challenge with CA-MRSA strain USA300 (p = 0.03). Furthermore, septic mice that received mAb treatment in conjunction with vancomycin exhibit less morbidity than mice treated with vancomycin alone. Taken together, these findings suggest that the contribution of SEK to S. aureus pathogenesis may be greater than previously appreciated, and that adjunctive therapy with passive immunotherapy against SEs may be beneficial.

AB - Staphylococcus aureus is a leading infectious cause of life-threatening disease in humans, yet there is currently no vaccine to combat this bacterium. The pathogenesis of S. aureus is mediated by a diverse array of protein toxins including a large family of secreted pyrogenic superantigens. Neutralization of superantigens, including SEB and TSST-1, has proven to be protective in several animal models of toxic shock and sepsis. We demonstrate, for the first time, that a far more prevalent staphylococcal superantigen, SEK, can also induce lethal shock in mice. Additionally, we describe monoclonal antibodies (mAbs) that inhibit SEK-induced mitogenicity as well as protect against SEK-induced lethality, and enhance survival from S. aureus septicemia in murine models. MAb-4G3 (IgG2b), mAb-5G2 (IgG1), and mAb-9H2 (IgG1), all inhibit SEK-induced proliferation and cytokine production of human immune cells. We then demonstrate that passive immunization with a combination of mAb-4G3 and mAb-5G4, 2 mAbs that do not compete for epitope(s) on SEK, significantly enhance survival in a murine model of SEK-induced toxic shock (p = 0.006). In the setting of sepsis, passive immunization with this combination of mAbs also significantly enhances survival in mice after challenge with CA-MRSA strain USA300 (p = 0.03). Furthermore, septic mice that received mAb treatment in conjunction with vancomycin exhibit less morbidity than mice treated with vancomycin alone. Taken together, these findings suggest that the contribution of SEK to S. aureus pathogenesis may be greater than previously appreciated, and that adjunctive therapy with passive immunotherapy against SEs may be beneficial.

KW - Staphylococcal Enterotoxin B

KW - Staphylococcal Enterotoxin K

KW - toxic shock syndrome toxin 1

UR - http://www.scopus.com/inward/record.url?scp=84992497980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992497980&partnerID=8YFLogxK

U2 - 10.1080/21505594.2016.1231295

DO - 10.1080/21505594.2016.1231295

M3 - Article

SP - 1

EP - 10

JO - Virulence

JF - Virulence

SN - 2150-5594

ER -